Ipilmumab and nivolumab together – pro
Nivolumab is a fully human IgG4 monoclonal antibody developed by Ono Pharmaceutical and Medarex for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells. In the United States, nivolumab is approved by the Food and Drug Administration for treatment of unresectable or metastatic melanoma who no longer respond to other drugs. 1 Iilimumab is also an effective drug for melanoma.
A recent phase I study preliminarily shows that concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients. 2 More recently, One- & Two-Year Survival Rates of 94% and 88% were Announced from this trial. However, this study is still ongoing and requires confirmation with longer term results and by other studies.
Opdivo, Prescribing information, 2015
Jedd D. Wolchok, M.D., Ph.D., Harriet Kluger, M.D., Margaret K. Callahan, M.D., Ph.D., Michael A. Postow, M.D., Naiyer A. Rizvi, M.D., Alexander M. Lesokhin, M.D., Neil H. Segal, M.D., Ph.D., Charlotte E. Ariyan, M.D., Ph.D., Ruth-Ann Gordon, B.S.N., Kathleen Reed, M.S., Matthew M. Burke, M.B.A., M.S.N., Anne Caldwell, B.S.N., Stephanie A. Kronenberg, B.A., Blessing U. Agunwamba, B.A., Xiaoling Zhang, Ph.D., Israel Lowy, M.D., Ph.D., Hector David Inzunza, M.D., William Feely, M.S., Christine E. Horak, Ph.D., Quan Hong, Ph.D., Alan J. Korman, Ph.D., Jon M. Wigginton, M.D., Ashok Gupta, M.D., Ph.D., and Mario Sznol, M.D. Nivolumab plus Ipilimumab in Advanced Melanoma. Engl J Med 2013; 369:122-133July 11, 2013
ASCO Post, ASCO 2014: Ipilimumab/Nivolumab Combination Achieves Long-Term Survival for Patients With Advanced Melanoma
By Charlotte Bath, Posted: 6/6/2014 2:58:04 PM. http://www.ascopost.com/ViewNews.aspx?nid=16293